Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. - Wikidata - wikimedia - TriplyDB

Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.

Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.

http://www.wikidata.org/entity/Q37393678

about

Lung function and airway obstruction: associations with circulating markers of cardiac function and incident heart failure in older men-the British Regional Heart Study COPD and stroke: are systemic inflammation and oxidative stress the missing links?From comorbidities of chronic obstructive pulmonary disease to identification of shared molecular mechanisms by data integration.Pulmonary artery to aorta ratio is associated with cardiac structure and functional changes in mild-to-moderate COPD Depression Is Associated with Readmission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease.Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease.Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations The clinical value of serial measurement of high-sensitivity cardiac troponin T in acute exacerbations ofchronic obstructive pulmonary disease.Alterations in the expression of the NF-κB family member RelB as a novel marker of cardiovascular outcomes during acute exacerbations of chronic obstructive pulmonary disease.Lung disease as a determinant of cognitive decline and dementia.Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study.Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer.Club Cell-16 and RelB as Novel Determinants of Arterial Stiffness in Exacerbating COPD Patients.Assessments of endothelial function and arterial stiffness are reproducible in patients with COPD.A Systematic Review of Diagnostic Biomarkers of COPD Exacerbation.COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry.Executive Function, Survival, and Hospitalization in Chronic Obstructive Pulmonary Disease. A Longitudinal Analysis of the National Emphysema Treatment Trial (NETT).Central arterial stiffness is increased among subjects with severe and very severe COPD: report from a population-based cohort study.B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review.C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations.No association between exacerbation frequency and stroke in patients with COPD.β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol Pulmonary Artery Enlargement Is Associated With Cardiac Injury During Severe Exacerbations of COPD The role of microparticles in chronic obstructive pulmonary disease Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFT® Trial Implications of the inflammatory response for the identification of biomarkers of chronic obstructive pulmonary disease.Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.Editor's Choice-Biomarkers of acute cardiovascular and pulmonary diseases.AIMAR survey on COPD phenotypes.Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care.Undiagnosed airflow limitation is common in patients with coronary artery disease and associated with cardiac stress.Clinical Characterization and Treatment Patterns for the Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease with Severe or Very Severe Airflow Limitation.Mechanisms of Chronic Obstructive Pulmonary Disease Exacerbations.Invasive coronary angiography in patients with acute exacerbated COPD and elevated plasma troponin.Differences in systemic adaptive immunity contribute to the 'frequent exacerbator' COPD phenotype.Impact and prevention of severe exacerbations of COPD: a review of the evidence.Cardiovascular Outcomes Following a Respiratory Tract Infection among Adults with Non-CF Bronchiectasis: A General Population Based Study.Chronic obstructive pulmonary disease: More than meets the eye.The role of beta-blockers in the management of chronic obstructive pulmonary disease.Microvascular dysfunction in silent myocardial ischemia.

P2860

Q24658577-BFA9407C-D04C-4185-93B1-1F5645671BAE Q26746530-F3BAA20F-877D-4A2A-8097-D59D5D95724F Q31160925-D085F44C-61A7-47DA-9BC0-C025C221AB6A Q33713681-C49A0DB0-78AE-4E5A-A08E-284BE6BD94EF Q33772323-E5F607A9-A959-4259-9249-AE12B6625D0C Q34042468-CB842104-E842-4B85-9797-E158DD9B2526 Q34062965-6AC70070-1A93-4ADE-9F9A-3734F4F151DE Q34304730-DB56B41C-1831-4DDD-86C2-A24FDEE094E0 Q34542055-C45717C7-88DC-4979-9550-14348E9342E0 Q35204219-BAD4BBFB-5CFB-4C07-BAF0-9EC48E8C3859 Q35871744-851B54DA-B3C0-445D-A3AD-E95215CA586F Q35897669-32017798-97C8-4E34-9690-FC7B1A828AC3 Q35935690-5A7ED78C-665B-4121-A016-ED632D5D19EB Q36079394-77EBA655-E8EB-4ADE-BFDB-771BE1FDFB83 Q36081606-B24D544B-9F4E-49F9-9EB2-AF8356D2C9A3 Q36104051-D9EB4E84-E712-4623-9FC7-9F491D78EE24 Q36232424-7E163CDE-293A-492D-8D0D-5DBB29CDD796 Q36239420-B4F28583-24EA-45F0-BA06-C7444434253D Q36245755-161A3534-542D-41AE-BE3A-93E7B5AD6D91 Q36318334-EB16DC78-F462-405E-9630-8C4BCC8710F2 Q36557662-B420F0CE-E2D8-4329-B5D9-CA175BC88A15 Q37006972-D83BCB84-5E5D-4B4D-8DBA-B3DEC188401D Q37094659-C3440A60-418A-42C0-B167-993A9AAC2A1C Q38202635-3047F3A0-AD4A-485A-9C1C-9F9B22714A39 Q38636054-C60B5396-C4FE-4D8C-ABB2-2F021A6A8152 Q38710985-AE3BE8C5-D71C-48A5-9100-4BBD39A0B2A3 Q38751226-ACB534E7-8C42-4736-9326-80D9BDD1B655 Q38843659-6BF2B8EB-624B-4F83-8284-429770E03541 Q38880954-3554AF58-4FF3-464B-9467-9678722D8BDF Q38944856-ED86F123-01C8-45E8-B278-7E79DA551CBC Q40383327-915DEF48-DD05-425E-B26B-104580712731 Q40484450-08A6F7DB-A380-4E57-8E2F-F77186A6B081 Q40899627-A04DC256-A218-40AE-A220-77F656A7839C Q41158533-BCDD01A5-DFD1-4877-9642-4C76780FAA53 Q41605285-A95E321F-72D2-4531-8824-ACFD1DDD5473 Q45803920-77319C7C-3B1B-4D3B-8256-2CA7623DFDE2 Q47268372-12E7C7F3-EF7B-4096-9FF4-CB788B7B80E5 Q47641727-BA54AD64-3CC7-4906-AC81-AF44627A4D37 Q47676572-1305A4C5-F04D-4ADD-9870-333BEF55A2C3 Q47900629-DA0CAE1B-DB1D-4DE2-8AAC-7C51992994F0

P2860

Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.

http://www.wikidata.org/entity/Q37393678

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Cardiovascular risk, myocardia ...... obstructive pulmonary disease.

@en

Cardiovascular risk, myocardia ...... obstructive pulmonary disease.

@nl

type

label

Cardiovascular risk, myocardia ...... obstructive pulmonary disease.

@en

Cardiovascular risk, myocardia ...... obstructive pulmonary disease.

@nl

prefLabel

Cardiovascular risk, myocardia ...... obstructive pulmonary disease.

@en

Cardiovascular risk, myocardia ...... obstructive pulmonary disease.

@nl

P1433

Q37393678-25B75269-B718-45B9-B1F5-13C9A581F95D

P1476

Q37393678-271139A9-ABAD-4F8C-AF5D-2B920BFC8AEC

P2093

Q37393678-41F123DD-298C-41C1-8BC3-1DF59A55B4BA

Q37393678-4B7C2D42-F0D0-4DAB-A047-7C6B2BE45877

Q37393678-69A8F9D2-49CE-438B-BDAC-430EE1778249

Q37393678-8BB01B0B-CCC0-4651-A6ED-E7C14078168E

Q37393678-A85B04A4-231F-4E54-9545-73D96295D229

Q37393678-B2CB9760-F17F-4F72-A513-9BDC551E8E53

Q37393678-B7CA6B46-5569-44B8-9D44-9923F98B151F

Q37393678-D8FBB00A-0B0B-43A1-9D84-8040EED9CC9D

P2860

Q37393678-0EC987C2-82E9-46F4-A2A1-071DE4CBA8C0

Q37393678-1BEA82A7-C058-47B7-89E7-4EFC2F4813BA

Q37393678-24DA9353-DCFB-4F10-889E-053197845C4B

Q37393678-25CD3D91-F918-488E-B563-80635F116826

Q37393678-2663BC77-1356-4BE7-A529-1A3881DD3DE0

Q37393678-297C02D0-35A5-4706-8C7A-0776FAB01C5A

Q37393678-36D383DA-481B-453F-895A-417594738AF0

Q37393678-3A7E8756-AA9F-4B31-85EC-9700DBDF28F0

Q37393678-3AF43505-EEFC-4AF2-9BDF-23B8ED7CA795

Q37393678-53A4497C-D3D0-495C-8629-236F22DC20AE

P304

Q37393678-9C4E51C5-2043-4B1E-8010-97E00D734421

P31

Q37393678-B17CCA82-ACBB-4B6B-91EB-CC2DCBE4DFA6

P356

Q37393678-276CA3D6-2A69-409F-B9D9-BDC9F4F759DE

P407

Q37393678-D14DFC7C-BFD3-4149-950F-B399781A9421

P433

Q37393678-1EBA46A4-C4D9-4E3E-BBEF-B23EF5FC6FF7

P478

Q37393678-1FE6541C-28DB-42E7-B0C2-CBA1FE6D4459

P50

Q37393678-B0D81699-9967-4D12-9F05-C79DA9AD5D51

P577

Q37393678-01A746E7-6403-41E1-8A20-D80B9005E71F

P5875

Q37393678-A6801EE0-2157-45AE-9666-0E93F9C1669A

P698

Q37393678-672F439B-1D63-4E68-A4A9-A6C6F039985C

P921

Q37393678-36EF2CE2-07B9-45A2-AF00-8E3C206FCE25

Q37393678-6666B1AC-2269-4B7D-9A9C-8947343ADEB5

P932

Q37393678-B04C568A-3560-4437-927A-31FC6F24A89B

P356

RCCM.201306-1170OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Cardiovascular risk, myocardia ...... obstructive pulmonary disease

@en

P2093

Anant R C Patel

http://www.w3.org/2001/XMLSchema#string

Beverly S Kowlessar

http://www.w3.org/2001/XMLSchema#string

Davinder S Garcha

http://www.w3.org/2001/XMLSchema#string

Gavin C Donaldson

http://www.w3.org/2001/XMLSchema#string

Jadwiga A Wedzicha

http://www.w3.org/2001/XMLSchema#string

John R Hurst

http://www.w3.org/2001/XMLSchema#string

Richa Singh

http://www.w3.org/2001/XMLSchema#string

Siobhan N George

http://www.w3.org/2001/XMLSchema#string

P2860

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals

Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin

Arterial stiffness and cardiovascular events: the Framingham Heart Study

Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD

Expert consensus document on arterial stiffness: methodological issues and clinical applications.

Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction.

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease.

P304

1091-1099

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201306-1170OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

188

http://www.w3.org/2001/XMLSchema#string

P50

Alexander J Mackay

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256607795

http://www.w3.org/2001/XMLSchema#string

P698

24033321

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

chronic obstructive pulmonary disease

P932

3863745

http://www.w3.org/2001/XMLSchema#string